Sesame Summit 2026 – application open

DiappyMed Raises €5M to Scale Digital Diabetes Therapy Across France

The digital therapeutics market for diabetes management is experiencing rapid growth across Europe, as healthcare systems increasingly recognise the potential of software-based interventions to improve patient outcomes and reduce costs. France, with an estimated 4.2 million people living with diabetes, stands at the forefront of this transformation — and one Montpellier-based startup is positioning itself to lead the charge.

DiappyMed, the French medtech company behind the clinically validated insulin dose calculation app EkiYou, has raised €5 million in a seed funding round. The investment was led by Ventech and AFI Ventures, with additional participation from Sofilaro and IRDI Capital Investissement. Alongside the raise, DiappyMed has announced a strategic partnership with pharmaceutical giant Sanofi to accelerate the deployment of its digital therapy across France.

Ventech and Sanofi Back Personalised Diabetes Care

The seed round marks a significant milestone for DiappyMed, which was founded in January 2021 following research conducted at Montpellier University Hospital by co-founder Omar Diouri. The company’s flagship product, EkiYou, is the first digital therapy application in France to have demonstrated clinically proven improvements in postprandial glycaemia within target range — a critical metric for effective diabetes management.

EkiYou works by calculating the appropriate insulin dose for patients based on their meals, physical activity levels, and blood glucose readings. The application effectively replaces the complex mental arithmetic that many insulin-dependent patients must perform daily, reducing dosing errors and improving glycaemic control. DiappyMed also launched EkiYou Carbs in November 2022, a complementary carbohydrate counting tool co-developed with Montpellier University Hospital.

The partnership with Sanofi is particularly noteworthy. The collaboration aims to massively deploy EkiYou as the first French digital therapy dedicated to personalised insulin
dose calculation for both healthcare professionals and patients living with diabetes. Sanofi’s involvement brings not only commercial reach but also deep expertise in insulin therapy, positioning DiappyMed at the intersection of pharmaceutical and digital health innovation.

European Digital Therapeutics Market Gains Momentum

DiappyMed’s raise arrives at an opportune moment for the digital therapeutics sector. The global market for digital therapeutics in diabetes management was valued at approximately $1.6 billion in 2023 and is projected to reach $5.3 billion by 2033, according to industry estimates. In Europe, regulatory frameworks are evolving to accommodate digital health solutions, with France’s health insurance system moving towards reimbursement of validated digital therapies.

Indeed, a central objective for DiappyMed is to achieve reimbursement from the French national health insurance (Assurance Maladie) in 2026. Securing reimbursement would represent a transformative moment for the company, as it would effectively integrate EkiYou into the standard care pathway for insulin-dependent diabetes patients across France — dramatically expanding its addressable market and providing a template for expansion into other European healthcare systems.

The €5 million investment will support DiappyMed’s pursuit of this reimbursement milestone, whilst also funding further clinical development, platform enhancements, and the scaling of its commercial partnership with Sanofi. As European healthcare systems grapple with rising diabetes prevalence and mounting treatment costs, digitally enabled solutions like EkiYou represent a compelling proposition for payers, providers, and patients alike.

Summary

Company DiappyMed
Headquarters Montpellier, France
Founded January 2021
Round Seed
Amount €5 million
Lead Investors Ventech, AFI Ventures
Other Investors Sofilaro, IRDI Capital Investissement
Strategic Partner Sanofi
Use of Funds Health insurance reimbursement, clinical development, Sanofi partnership scaling

you might also like

Fundraising 4 hours ago

London-based AI laboratory Ineffable Intelligence has emerged from stealth with a $1.1 billion seed round at a $5.1 billion post-money valuation, the company confirmed on 27 April 2026. The financing is the largest seed round ever raised by a European company and one of the largest first-money-in rounds in the global history of artificial intelligence. The round was co-led by Sequoia Capital and Lightspeed Venture Partners. Participating investors included Nvidia, DST Global, Index Ventures, Google, and the UK Sovereign AI Fund, the British government’s recently established vehicle for backing strategic AI capacity on home soil. A bet on a different path to general intelligence Ineffable Intelligence was founded in 2025 by David Silver, the former Vice President of Reinforcement Learning at Google DeepMind and the principal architect of AlphaGo, AlphaZero and AlphaStar. He is joined by three further DeepMind alumni: Wojciech Czarnecki, Lasse Espeholt and Junhyuk Oh. All four have spent the past decade at the frontier of reinforcement learning research, the discipline behind some of the most consequential demonstrations of machine learning over the past ten years. The company describes its objective as building a “superlearner” — an AI system capable of acquiring knowledge directly from its own experience rather than from human-generated text or imagery. “Our mission is to make first contact with superintelligence,” Silver said in a statement accompanying the launch. “We are creating a superlearner that discovers all knowledge from its own experience, from elementary motor skills through to profound intellectual breakthroughs.” The framing is a deliberate departure from the dominant industry trajectory. Most leading AI laboratories, including OpenAI, Anthropic and Google DeepMind itself, have built large language models trained primarily on the corpus of the internet, then refined that training with human feedback. Ineffable’s wager is that the marginal returns on scaling text-based pretraining are diminishing and that the next leap in capability will come from agents that learn endlessly from the consequences of their own actions, in much the same way AlphaZero learnt the game of Go without studying any human matches. Why $1.1 billion at seed The size of the round is unusual even by the inflated standards of the 2026 AI capital cycle. Two factors appear to explain it. First, frontier reinforcement learning at the scale Ineffable describes is computationally extraordinarily expensive: the company will need to operate vast simulation environments and train very large models against them, an undertaking that consumes capital at a rate closer to physical R&D than to traditional software. Second, the round signals a strategic move by Europe’s investor and policy ecosystems to retain the most ambitious AI researchers on the continent. The presence of the UK Sovereign AI Fund alongside Sequoia, Lightspeed and Nvidia is the clearest expression of that intent. The British government has publicly framed the investment as a bet on breakthrough AI that “can discover new knowledge”, positioning the country as a willing co-investor in domestic frontier laboratories. For Ineffable, the implication is access not only to capital but to compute, regulatory engagement and the still-resilient academic talent base around UCL, Oxford, Cambridge and Imperial. Founder pledge of historic scale Alongside the funding announcement, Silver disclosed that he is committing 100 per cent of any personal proceeds from his Ineffable equity to charity via the Founders Pledge network — described by the organisation as the largest pledge in its history. At the round’s $5.1 billion valuation, that commitment could ultimately exceed several billion dollars if the company succeeds. It is a meaningful gesture in a sector where the reputational stakes around concentrated AI wealth are escalating, and one likely to be referenced in subsequent founder-led commitments. Implications for the European AI landscape Ineffable’s emergence reshapes the European AI map in three concrete ways. It establishes London as the home of the continent’s largest-ever seed-stage company, complicating Paris’s recent narrative of frontier-AI primacy after Mistral’s earlier rounds. It validates a thesis — that reinforcement learning, not transformer scaling, is the next frontier — that has lately been losing capital share to language-model incumbents. And it confirms that the UK government is now willing to act as a balance-sheet co-investor in domestic AI laboratories, a posture much closer to the French model than to the predominantly grant-based regimes elsewhere in Europe. The execution risk is non-trivial. Reinforcement learning at frontier scale has historically required years of careful environment design before producing competitive systems, and Ineffable’s “first contact” framing sets a high bar against which it will be judged. But for now, with a billion dollars on the balance sheet, four of the discipline’s most accomplished researchers in the founding team and a sovereign co-investor at its back, Ineffable Intelligence is the most heavily resourced new entrant in the European AI cycle. Sesamers covers European fundraising rounds across deeptech, fintech and AI. Source: tech.eu.

Fundraising 5 days ago

Belfast's Cloudsmith has raised $72M Series C led by TCV, with Insight Partners participating, to expand its artifact management platform and secure the AI-era software supply chain.

Fundraising 5 days ago

Berlin’s VREY has raised €3.3M seed led by Rubio Impact Ventures to roll out rooftop solar software for Germany’s multi-family buildings.

Subscribe to
our Newsletter!

Stay at the forefront with our curated guide to the best upcoming Tech events.